We hereby confirm the findings of Jonasson et al. (2016) who reported that among Icelandic BRCA2 carriers, ER-positive status was an adverse prognostic factor.10 Their study included 285 breast cancer patients with a 999del5 BRCA2 mutation, matched with 570 non-carrier patients. This evidence concerns the gene BRCA2 and breast cancer.